Destructive bacterial inflammations represent a group of severe infections characterized by tissue necrosis, systemic inflammatory response, and often life-threatening complications. The present study investigates the etiological structure, evolving microbial spectrum, and the dynamics of antibiotic susceptibility in patients diagnosed with destructive infectious diseases. Microbiological analysis of clinical specimens from 400 patients revealed a dominance of multidrug-resistant (MDR) pathogens, including MRSA, ESBL-producing Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii. Antibiotic susceptibility testing showed a progressive decline in carbapenem effectiveness, with colistin and glycopeptides retaining relatively high activity. The study emphasizes the importance of continuous microbiological monitoring and personalized empirical therapy protocols based on local resistance patterns.

Destructive inflammation, multidrug-resistant bacteria, antimicrobial resistance, microbiological surveillance, empirical antibiotic therapy, MRSA, ESBL, carbapenem-resistant pathogens.

Brook I. Microbiology and management of pleural empyema in children. Pediatr Pulmonol. 2020;55(5):1234–1240.

Mandell LA, et al. Infectious Diseases: Principles and Practice. 9th ed. Elsevier; 2019.

Rice LB. Mechanisms of resistance and clinical relevance of resistance to β-lactams, glycopeptides, and fluoroquinolones. Mayo Clin Proc. 2005;80(6):945–955.

Tacconelli E, et al. Global priority list of antibiotic-resistant bacteria. Lancet Infect Dis. 2018;18(3):318–327.

CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 33rd ed. 2023.

WHO. Global action plan on antimicrobial resistance. Geneva: World Health Organization; 2022.

ECDC. Surveillance of antimicrobial resistance in Europe. 2023.

Livermore DM. Current epidemiology and emerging resistance threats. J Antimicrob Chemother. 2018;73(3):ii1–ii6.

Spellberg B, et al. The future of antibiotics and resistance. N Engl J Med. 2013;368(4):299–302